Tempus AI's Strategic Push to Expand Beyond Oncology

TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach.

Zacks Investment Research • Dec 11, 2025

Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition?

Tempus AI's shift toward scalable revenues, high-margin data services and broader AI capabilities defines a pivotal moment for TEM investors.

Zacks Investment Research • Dec 10, 2025

Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?

Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.

Zacks Investment Research • Dec 9, 2025

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas. “This year at SABCS, our research highlights the power of multimodal data to help unravel the complexity of breast cancer,” said Ez.

Business Wire • Dec 9, 2025

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood bought shares of Baidu, WeRide, and Tempus AI on Monday. Baidu has rallied on its rising AI chips business in China, but it's still textbook cheap.

The Motley Fool • Dec 9, 2025

Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook

Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.

Zacks Investment Research • Dec 8, 2025

Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies.

The Motley Fool • Dec 5, 2025

Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves

TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.

Zacks Investment Research • Dec 5, 2025

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

Zacks Investment Research • Dec 5, 2025

Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report?

Tempus (TEM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025